GGrantIndex
← Search

Shared Resource Management (SRM)

$144,525P30FY2025CANIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications, trials & patents

Trial NCT07339085Trial NCT07276438Trial NCT07242365Trial NCT06650163Trial NCT06568016Trial NCT06113016Trial NCT05595499Trial NCT04205838Trial NCT04201873Trial NCT04185311Trial NCT04119024Trial NCT04106362Trial NCT04069923Trial NCT04069910Trial NCT04050215Trial NCT04007029Trial NCT03996850Trial NCT03970252Trial NCT03953157Trial NCT03904251Trial NCT03902951Trial NCT03892720Trial NCT03830918Trial NCT03825796Trial NCT03745690Trial NCT03732950Trial NCT03732352Trial NCT03672773Trial NCT03623854Trial NCT03618134Trial NCT03603223Trial NCT03601455Trial NCT03596710Trial NCT03582774Trial NCT03582475Trial NCT03541850Trial NCT03515577Trial NCT03506802Trial NCT03425461Trial NCT03411070Trial NCT03368547Trial NCT03319342Trial NCT03240861Trial NCT03202472Trial NCT03128619Trial NCT03025139Trial NCT03014804Trial NCT02940262Trial NCT02928510Trial NCT02925351Trial NCT02919332Trial NCT02902757Trial NCT02888301Trial NCT02881242Trial NCT02880020Trial NCT02879994Trial NCT02830165Trial NCT02816879Trial NCT02775292Trial NCT02756130Trial NCT02701153Trial NCT02688348Trial NCT02683200Trial NCT02672033Trial NCT02597894Trial NCT02575027Trial NCT02451865Trial NCT02336763Trial NCT02310594Trial NCT02296229Trial NCT02280161Trial NCT02263898Trial NCT02176902Trial NCT02070406Trial NCT02049593Trial NCT02048020Trial NCT02015559Trial NCT01912820Trial NCT01013285Trial NCT01005472Trial NCT00999557Trial NCT00998010Trial NCT00985192Trial NCT00955591Trial NCT00882765Trial NCT00880542Trial NCT00769470Trial NCT00706615Trial NCT00685516Trial NCT00616642Trial NCT00612066Trial NCT00601289Trial NCT00601094Trial NCT00521209Trial NCT00509431Trial NCT00471887Trial NCT00450567Trial NCT00444223Trial NCT00352001Trial NCT00349167

Abstract

SHARED RESOURCE MANAGEMENT ABSTRACT The UCLA Jonsson Comprehensive Cancer Center (JCCC) oversees six Shared Resources (SRs), which are most essential for basic, clinical, translational, and population science cancer research by Center investigators in support of the JCCC mission, to accelerate discoveries to prevent and cure cancer. JCCC SRs include Biostatistics, Analytical Support, and Evaluation (BASE) SR, Flow Cytometry SR (FCSR), Genomics SR (GSR), Molecular Screening SR (MSSR), Small Animal Imaging SR (SAISR), and the Translational Pathology Core Laboratory (TPCL) SR. JCCC SRs deliver high quality, state-of-the-art technologies and expertise to JCCC researchers engaged in broad spectrum cancer-related studies. The JCCC provides scientific, administrative, and financial support and oversight of SRs to ensure cost-effective, priority access for JCCC investigators to basic, advanced, and cutting-edge equipment and specialized services. Since the 2019 NCI Cancer Center Support Grant (CCSG) renewal, Zoran Galic, PhD (TII), AD for SRs, has significantly enhanced the management of JCCC SRs. Galic implemented measures for structured oversight, established advisory committees, implemented formal mechanisms to obtain JCCC user feedback, and increased the visibility of SRs within the cancer research community. He organizes a monthly SR Directors Meeting, an every-other-month SR Oversight Committee (SROC) meeting, twice annual Early-Stage Investigators Committee (ESIC) meetings, and he participates in Faculty Advisory Committees (FAC) meetings for each SR. By organizing these and additional management meetings and activities, Galic has been pivotal in aligning SR functions with the strategic goals of the JCCC. Notable achievements during his tenure include facilitating acquisition of >$8.1M of new high-end instrumentation and enhancements to the technological expertise of the SRs. He works to ensure resources are available to meet emergent needs of JCCC investigators by expansion or addition of new SR capabilities and he supports the professional development of SR personnel. By establishing robust and periodically updated management policies and procedures, Galic helps to guarantee that the SRs offer highest quality, cost-effective, JCCC investigator prioritized, and responsive services that meet or exceed the needs of the cancer research community and the strategic objectives of the JCCC. From 2019 – 2023, JCCC SRs provided services to 219 different JCCC investigator laboratories, facilitating 679 cancer-related publications, 42% in high-impact (IF ≥10) journals, and supporting over $305M in total cancer-related extramural research funding. Recognizing the indispensable role of SRs in achieving breakthroughs in cancer research, the JCCC has committed to further enhancing and evolving SR technologies, services, activities, and offerings in its next period 2024 – 2028 Strategic Plan, ensuring that SRs continue to support impactful cancer research and treatment advancements near and long-term.

View original record on NIH RePORTER →